Operating performance above est.; FY25 outlook better

28 May 2024
5 Min read 
  • Glenmark Pharma's financials and valuations have changed, leading to a change in target price and rating.
  •  The company's operating performance exceeded expectations, with better profitability and lower raw material costs.
  •  Glenmark Pharma took a significant impairment charge on manufacturing facilities and intangibles during the quarter.
  •  Earnings estimates have been raised for FY25 and FY26 due to new launches and increased market share.
  •  The company's revenue grew in various segments, including domestic formulations, the US, Europe, and RoW.
  •  Glenmark Pharma's shareholding pattern, management commentary, and financial indicators have been highlighted.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority